Precision therapy for non-small cell lung cancer (NSCLC) could save patients’ lives, but access to these treatments and the required genomic and biomarker testing are out of reach for many. In a new OncLive interview, Ashling Wahner talks about recently presented research into the impact of targeted therapy, or the lack thereof, with the VP of Science Policy at the Personalized Medicine Coalition Daryl Pritchard, PhD.
According to Pritchard, “This research was interesting, and it corroborated much of what the community was thinking. Most importantly, it shows this in a real-world evidence paradigm. These practice-based data show the great value of targeted treatments to lung cancer patients at an advanced stage. Secondly, it shows some of the clinical practice challenges, or clinical practice gaps, that are impeding the delivery of targeted therapies to patients. It highlights, or sets an alarm, that we need to address those clinical practice challenges.”
To read more, click here.
(Source: OncLive, March 14th, 2023)
